Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Acquires $21,760.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar bought 8,000 shares of the company’s stock in a transaction dated Thursday, October 22nd. The stock was acquired at an average price of $2.72 per share, for a total transaction of $21,760.00. Following the acquisition, the chief executive officer directly owned 680,000 shares in the company, valued at $1,849,600. This trade represents a 1.19% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 24th, Amit Kumar bought 7,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $2.78 per share, with a total value of $19,460.00.
• On Thursday, September 10th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $2.75 per share, with a total value of $8,250.00.
• On Thursday, September 10th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average cost of $2.76 per share, with a total value of $13,800.00.
• On Friday, July 31st, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were acquired at an average cost of $3.47 per share, for a total transaction of $17,350.00.
• On Friday, July 24th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The stock was bought at an average cost of $3.37 per share, with a total value of $10,743.56.
• On Monday, July 27th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.44 per share, for a total transaction of $17,200.00.

Anixa Biosciences Stock Performance

Shares of NASDAQ ANIX opened at $2.99 on Friday. The business’s 50-day simple moving average is $3.00 and its 200-day simple moving average is $2.98. Anixa Biosciences Inc has a 52 week low of $2.32 and a 52 week high of $5.46. The firm has a market cap of $103.93 million, a price-to-earnings ratio of -9.34 and a beta of 0.47.

Anixa Biosciences (NASDAQ:ANIX) last posted its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). As a group, equities research analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have weighed in on ANIX shares. HC Wainwright reduced their price target on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 22nd. D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Zacks Research cut Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Weiss Ratings raised Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. Finally, Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $8.00.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in ANIX. Renaissance Technologies LLC raised its stake in shares of Anixa Biosciences by 13.6% during the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after buying an additional 7,300 shares during the last quarter. CoreCap Advisors LLC grew its holdings in Anixa Biosciences by 19.2% during the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after purchasing an additional 10,000 shares during the period. Sanctuary Advisors LLC bought a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Northwestern Mutual Wealth Management Co. bought a new stake in Anixa Biosciences in the second quarter valued at approximately $29,000. Finally, Integrated Wealth Concepts LLC bought a new stake in Anixa Biosciences in the second quarter valued at approximately $30,000. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. The company’s programs are designed to use the immune system to identify and attack disease-associated targets.

Anixa’s oncology pipeline has included a chimeric antigen receptor T-cell (CAR-T) therapy targeting the follicle-stimulating hormone receptor, which is being investigated as a potential treatment for ovarian cancer and other cancers.